Clinical trial · Interventional
18F-FAPIBiotin PET/CT: Dosimetry and Biodistribution Study
18F-FAPIBiotin PET/CT: Dosimetry and Biodistribution Study in Patients With Various Cancers
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
As a new dual targeting PET radiotracer, 18F-FAPI-Biotin is promising as an excellent imaging agent applicable to various cancers. In this study, we observed the safety, biodistribution and radiation dosimetry of 18F-FAPI-Biotin in patients with various types of cancer and compared them with the results of 18F-FAPI or 18F-FDG imaging to evaluate the dosimetric characteristics and diagnostic efficacy of 18F-FAPI.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Malignant Neoplasm | Malignant Neoplasm | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 18F-FAPIBiotin | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- dynamic PET scans
- description
- PET imaging will begin at 3 minutes, 15 minutes, 30min minutes, 60 minutes and 120 minutes after injection.
- interventionNames
- Drug: 18F-FAPIBiotin
Primary outcomes (1)
- measure
- Dosimetry of normal organs and tumors
- timeFrame
- From right after tracer injection to 120 minutes at post-injection
- description
- The semiquantitative dosimetry will be performed based on PET/CT acquisitions after the first administration of 18F-FAPI-Biotin. The dose delivered to normal organs and tumors will be recorded.
Secondary outcomes (1)
- measure
- Incidence of Adverse events were categorized using the Common Toxicity Criteria for Adverse Events 5.0.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Various solid tumors with available histopathological findings • Signed informed consent Exclusion Criteria: * pregnant or lactational women • who suffered from severe hepatic and renal insufficiency
References
Publications (0)
Data not yet available